Sarawak General Hospital is the largest hospital in the state of Sarawak, Malaysia. It is the main tertiary and referral hospital in East Malaysia. In its earlier years it was known as Kuching General Hospital.

There are 1,005 beds in Sarawak General Hospital.

During the past decade, Sarawak General Hospital conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 24 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 43 clinical trials started and 18 clinical trials were completed. i.e. 41.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarawak General Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 11 trials, followed by "Pfizer" with 6 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "University of Malaya" with 4 trials sponsored and "Baxalta now part of Shire" with 4 trials sponsored. Other sponsors include 59 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarawak General Hospital" #1 collaborator was "Sarawak General Hospital" with 4 trials as a collaborator, "CardioVascular Research Foundation, Korea" with 3 trials as a collaborator, "Hospital Enche Besar Hajjah Khalsom, Kluang, Johor" with 2 trials as a collaborator, "Hospital Melaka, Melaka" with 2 trials as a collaborator and "Hospital Queen Elizabeth, Malaysia" with 2 trials as a collaborator. Other collaborators include 70 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "Sarawak General Hospital" are "COVID-19" (4 trials), "Arthritis, Rheumatoid" (3 trials), "Coronary Artery Disease" (3 trials), "Hemophilia A" (3 trials) and "Anosmia" (2 trials). Many other conditions were trialed in "Sarawak General Hospital" in a lesser frequency.

Most popular intervention types in "Sarawak General Hospital" are "Drug" (66 trials), "Other" (14 trials), "Biological" (9 trials), "Device" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Carboplatin" (4 trials), "Paclitaxel" (4 trials), "PTG-300" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sarawak General Hospital" are 86 trials for "All" genders, 5 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Sarawak General Hospital". undefined are not yet recruiting, 25 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in Sarawak General Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Sarawak General Hospital, 3 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 7 trials that are defined as “Not Applicable".